Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -49.86% | 46.15% | |||
| Gross Profit | 49.86% | -46.15% | |||
| SG&A Expenses | 12.77% | -8.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.28% | 21.92% | |||
| Operating Income | 31.28% | -21.92% | |||
| Income Before Tax | 27.51% | -12.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.51% | -12.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.51% | -12.74% | |||
| EBIT | 31.28% | -21.92% | |||
| EBITDA | 31.38% | -21.89% | |||
| EPS Basic | 27.88% | 9.21% | |||
| Normalized Basic EPS | 33.49% | 1.52% | |||
| EPS Diluted | 27.88% | 9.21% | |||
| Normalized Diluted EPS | 33.49% | 1.52% | |||
| Average Basic Shares Outstanding | 0.53% | 24.23% | |||
| Average Diluted Shares Outstanding | 0.53% | 24.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||